{
    "clinical_study": {
        "@rank": "33532", 
        "arm_group": [
            {
                "arm_group_label": "Tarceva + gemcitabine/platinum", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo + gemcitabine/platinum", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy and safety of sequential administration of Tarceva and\n      gemcitabine/platinum chemotherapy in patients with stage IIIb/IV non-small cell lung cancer.\n      Patients will be randomized to receive Tarceva (150mg po) or placebo on days 15-28 of a 4\n      week cycle of intravenous platinum-based chemotherapy, for a total of 6 cycles. The\n      anticipated time on study treatment is until disease progression or unacceptable toxicity."
        }, 
        "brief_title": "A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.", 
        "completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "condition": "Non-Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adult patients, >=18 years of age;\n\n          -  histologically documented advanced or recurrent stage IIIB or IV non-small cell lung\n             cancer;\n\n          -  measurable disease;\n\n          -  no previous chemotherapy for non-small cell lung cancer.\n\n        Exclusion Criteria:\n\n          -  unstable systemic disease;\n\n          -  any other malignancies in the last 5 years."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "154", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01998919", 
            "org_study_id": "MO18633"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tarceva + gemcitabine/platinum", 
                "description": "150 mg orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by 150 mg orally daily", 
                "intervention_name": "erlotinib [Tarceva]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo + gemcitabine/platinum", 
                "description": "orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by daily oral application", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Tarceva + gemcitabine/platinum", 
                    "Placebo + gemcitabine/platinum"
                ], 
                "description": "1250 mg/m2 iv Days 1 and 8 of each 4-week cycle, 6 cycles", 
                "intervention_name": "gemcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Tarceva + gemcitabine/platinum", 
                    "Placebo + gemcitabine/platinum"
                ], 
                "description": "75 mg/m2 iv Day 1 of each 4.wek cycle, 6 cycles; or carboplatin", 
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Tarceva + gemcitabine/platinum", 
                    "Placebo + gemcitabine/platinum"
                ], 
                "description": "5 x AUC iv Day 1 of each 4.week cycle, 6 cycles; or cisplatin", 
                "intervention_name": "carboplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin", 
                "Carboplatin", 
                "Erlotinib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Campbelltown", 
                        "country": "Australia", 
                        "zip": "2560"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Camperdown", 
                        "country": "Australia", 
                        "zip": "2050"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liverpool", 
                        "country": "Australia", 
                        "zip": "2170"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "zip": "510060"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "zip": "510080"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200433"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200030"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jakarta", 
                        "country": "Indonesia", 
                        "zip": "10430"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jakarta", 
                        "country": "Indonesia", 
                        "zip": "10410"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jogjakarta", 
                        "country": "Indonesia", 
                        "zip": "55284"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Semarang", 
                        "country": "Indonesia", 
                        "zip": "50136"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyunggi-do", 
                        "country": "Korea, Republic of", 
                        "zip": "411-769"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manila", 
                        "country": "Philippines", 
                        "zip": "1000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Metro Manila", 
                        "country": "Philippines", 
                        "zip": "1502"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "100"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10400"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10700"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "China", 
                "Hong Kong", 
                "Indonesia", 
                "Korea, Republic of", 
                "Philippines", 
                "Taiwan", 
                "Thailand"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Placebo-controlled, Double-blind Phase II of Sequential Administration of Tarceva (Erlotinib) or Placebo in Combination With Gemcitabine/Platinum as First-line Treatment in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC).", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Hong Kong: The Government of the Hong Kong Special Administrative Region"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Non-progression rate (complete response, partial response, stable disease)", 
            "safety_issue": "No", 
            "time_frame": "approximately 18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01998919"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective response rate (complete response and partial response)", 
                "safety_issue": "No", 
                "time_frame": "approximately 18 months"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "approximately 5 years"
            }, 
            {
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "approximately 5 years"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 5 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 5 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2006", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}